An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors and in Adult Patients With Recurrent or Progressive Glioblastoma or High-grade Glioma
Phase of Trial: Phase I/II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Lisavanbulin (Primary)
- Indications Cholangiocarcinoma; Glioblastoma; Glioma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Basilea Pharmaceutica
- 03 Jan 2018 According to a Basilea Pharmaceutica media release, recruitment in phase 1 part of solid tumor arm has been completed. The recruitment in phase 1 part of glioblastoma arm is expect to complete in first half of 2018. Also, company plans to present phase 1 results at upcoming scientific conferences.
- 10 Aug 2017 According to a company media release, Basilea anticipates completing patient recruitment into the this trial by end of this year. Completion of patient recruitment into the separate glioblastoma study arm is expected in the first half of 2018.
- 12 Jun 2017 According to a Basilea Pharmaceutica Ltd. media release, the Adult Brain Tumor Consortium (ABTC) will conduct a the phase 1 part of this study.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History